Market Place
Sourcing Support
Praxis Precision Medicines Submits Ulixacaltamide Hcl Nda
14 Apr 2026 //
GLOBENEWSWIRE
Praxis To Present Essential3 Phase 3 Success In Essential Tremor
13 Apr 2026 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Positive EMBRAVE Data
06 Apr 2026 //
GLOBENEWSWIRE
Praxis Precision Gets FDA Priority Review for Relutrigine in DEEs
30 Mar 2026 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Mar 2026 //
GLOBENEWSWIRE
Praxis Precision Medicines To Release Q4 2025 Financials, Join
09 Feb 2026 //
GLOBENEWSWIRE
Praxis Precision Announces Inducement Grants Under Nasdaq LR
04 Feb 2026 //
GLOBENEWSWIRE
Praxis Precision Pharma Advances After A Key Year Of Achievements
12 Jan 2026 //
GLOBENEWSWIRE
Praxis Precision Announces Inducement Grants LR 5635(c)(4)
09 Jan 2026 //
GLOBENEWSWIRE
Praxis Precision Pharma Boosts Growth With Key Board
08 Jan 2026 //
GLOBENEWSWIRE
Praxis Precision Medicines Gets FDA Breakthrough Status
29 Dec 2025 //
GLOBENEWSWIRE
Praxis Aligns with FDA on Elsunersen for SCN2A
09 Dec 2025 //
GLOBENEWSWIRE
Praxis Leads in Rare Pediatric & Adult Epilepsies at AES
08 Dec 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Positive EMBOLD Study Results
04 Dec 2025 //
GLOBENEWSWIRE
FDA Clears Ulixacaltamide Pre-NDA for Essential Tremor
04 Dec 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Nasdaq Inducement Grants
03 Dec 2025 //
GLOBENEWSWIRE
Praxis Presents Epilepsy Advances at the 2025 AES Meeting
24 Nov 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Inducement Grants Under
06 Nov 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Joins Investor Conferences
05 Nov 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Q3 2025 Results, Update
05 Nov 2025 //
GLOBENEWSWIRE
Praxis Gets Accelerated Path for Relutrigine in SCN2A & SCN8A DEE
04 Nov 2025 //
GLOBENEWSWIRE
Praxis Surges With Drug Enhancing Function In Movement Disorder
16 Oct 2025 //
REUTERS
Praxis Precision Medicines Reports Positive Phase 3 Results
16 Oct 2025 //
GLOBENEWSWIRE
Praxis Precision Medicine Induces Grants Per Nasdaq LR 5635(c)(4)
02 Oct 2025 //
GLOBENEWSWIRE
Recode Therapeutics Secures $29m For Genetic Medicines Pipeline
29 Sep 2025 //
BUSINESSWIRE
Praxis Precision Medicines Joins September Investor Conferences
04 Sep 2025 //
GLOBENEWSWIRE
Praxis Medicines to Present at 36th Epilepsy Congress 2025
25 Aug 2025 //
GLOBENEWSWIRE
Praxis` Drug Reduces Seizures but Sees 23% Discontinuation Rate
05 Aug 2025 //
FIERCE BIOTECH
Praxis Announces Q2 2025 Financials & RADIANT Trial Results
29 Jul 2025 //
GLOBENEWSWIRE
Praxis Grants Equity Awards Under Nasdaq LR 5635(c)(4)
04 Jun 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Updates DEE Clinical Program at Event
05 May 2025 //
GLOBENEWSWIRE
Praxis Precision to Present Late-Stage Programs at AAN Meeting
24 Mar 2025 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Mar 2025 //
GLOBENEWSWIRE
Praxis moves ahead despite phase 3 tremor trial futility finding
28 Feb 2025 //
FIERCE BIOTECH
Praxis Provides Update On Essential3 & Corporate Strategy
28 Feb 2025 //
GLOBENEWSWIRE
Praxis To Participate In Upcoming Investor Conferences
05 Sep 2024 //
GLOBENEWSWIRE
Praxis To Present Epilepsy Portfolio At ILAE Congress
04 Sep 2024 //
GLOBENEWSWIRE
Praxis To Announce Phase 2 EMBOLD Study Data For Relutrigine On Sept 3, 2024
02 Sep 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines To Report Q2 2024 Results On August 13
05 Aug 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Receives PRIME Designation from EMA for elsunersen
16 Nov 2023 //
GLOBENEWSWIRE
